These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 3548268)

  • 1. Effect of ciladopa on Parkinson's disease: a preliminary report.
    Weiner WJ; Berger JR
    Adv Neurol; 1987; 45():583-6. PubMed ID: 3548268
    [No Abstract]   [Full Text] [Related]  

  • 2. A double-blind evaluation of ciladopa in Parkinson's disease.
    Weiner WJ; Factor SA; Sanchez-Ramos J; Berger J
    Mov Disord; 1987; 2(3):211-7. PubMed ID: 3332914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parallel double-blind study of pergolide in Parkinson's disease.
    Jankovic J; Orman J
    Adv Neurol; 1987; 45():551-4. PubMed ID: 3548265
    [No Abstract]   [Full Text] [Related]  

  • 4. [Physiological trials with MIF-I in Parkinson's disease (author's transl)].
    Gonce M; Barbeau A
    Rev Neurol (Paris); 1978 Feb; 134(2):141-9. PubMed ID: 29330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Preliminary clinical trial of tetrahydropapaveroline in Parkinson's disease].
    Dordain G; Goujet MA; Simon P
    Therapie; 1974; 29(3):421-34. PubMed ID: 4612860
    [No Abstract]   [Full Text] [Related]  

  • 6. A double-blind controlled study of MK-486 in Parkinson's disease.
    Schwartz AM; Olanow CW; Spencer A
    Trans Am Neurol Assoc; 1973; 98():301-3. PubMed ID: 4594189
    [No Abstract]   [Full Text] [Related]  

  • 7. The use of dopaminergic receptor stimulating agent (Pribedil, ET 495) in Parkinson's disease.
    Lieberman A; Le Brun Y; Boal D; Zolfaghari M
    Adv Biochem Psychopharmacol; 1974; 12(0):415-25. PubMed ID: 4425258
    [No Abstract]   [Full Text] [Related]  

  • 8. Pramipexole and ropinirole for Parkinson's disease.
    Med Lett Drugs Ther; 1997 Nov; 39(1014):109-10. PubMed ID: 9398824
    [No Abstract]   [Full Text] [Related]  

  • 9. A trial of dextromethorphan in parkinsonian patients with motor response complications.
    Verhagen Metman L; Blanchet PJ; van den Munckhof P; Del Dotto P; Natté R; Chase TN
    Mov Disord; 1998 May; 13(3):414-7. PubMed ID: 9613730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Flumazenil, a GABA antagonist, may improve features of Parkinson's disease.
    Ondo WG; Hunter C
    Mov Disord; 2003 Jun; 18(6):683-5. PubMed ID: 12784272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zolpidem in Parkinson's disease.
    Daniele A; Albanese A; Gainotti G; Gregori B; Bartolomeo P
    Lancet; 1997 Apr; 349(9060):1222-3. PubMed ID: 9130951
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment of Parkinson's disease with ciladopa.
    Aminoff MJ; Goodin DS; Habermann-Little B; Cutler JR
    Ann Neurol; 1987 Mar; 21(3):311. PubMed ID: 3606037
    [No Abstract]   [Full Text] [Related]  

  • 13. Mesulergine (CU32-085) in the treatment of Parkinson's disease.
    Pfeiffer RF; Wilken K; Glaeske C
    Ann Neurol; 1985 Apr; 17(4):334-6. PubMed ID: 3890700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SLV-308. Solvay.
    Wolf WA
    Curr Opin Investig Drugs; 2003 Jul; 4(7):878-82. PubMed ID: 14619412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parenteral ziprasidone: a new atypical neuroleptic for emergency treatment of psychosis in Parkinson's disease?
    Oechsner M; Korchounov A
    Hum Psychopharmacol; 2005 Apr; 20(3):203-5. PubMed ID: 15799011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical use of levodopa in the treatment of Parkinson's disease.
    McDowell FH; Markham CH; Lee JE; Treciokas LJ; Ansel RD
    Contemp Neurol Ser; 1971; 8():175-201. PubMed ID: 4950056
    [No Abstract]   [Full Text] [Related]  

  • 17. Abnormal excitability of premotor-motor connections in de novo Parkinson's disease.
    Buhmann C; Gorsler A; Bäumer T; Hidding U; Demiralay C; Hinkelmann K; Weiller C; Siebner HR; Münchau A
    Brain; 2004 Dec; 127(Pt 12):2732-46. PubMed ID: 15509619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of memantine (NMDA antagonist) on Parkinson's disease: a double-blind crossover randomized study.
    Merello M; Nouzeilles MI; Cammarota A; Leiguarda R
    Clin Neuropharmacol; 1999; 22(5):273-6. PubMed ID: 10516877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ropinirole in the treatment of early Parkinson's disease: a 6-month interim report of a 5-year levodopa-controlled study. 056 Study Group.
    Rascol O; Brooks DJ; Brunt ER; Korczyn AD; Poewe WH; Stocchi F
    Mov Disord; 1998 Jan; 13(1):39-45. PubMed ID: 9452324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A six-month study of pergolide and levodopa in de novo Parkinson's disease patients.
    Kulisevsky J; López-Villegas D; García-Sánchez C; Barbanoj M; Gironell A; Pascual-Sedano B
    Clin Neuropharmacol; 1998; 21(6):358-62. PubMed ID: 9844794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.